Roche and its Genentech division have tapped data curation developer Flywheel to help train its machine learning models aimed at discovering potential new drugs.
Connect Biopharma touts positive results for Dupixent rival, but shares halved as investors await hard data
Connect Biopharma connected to the investor community Friday, but not in the way it wanted, as its stock sunk 57% by end of trading on what it touted as positive data for its eczema asset.
After picking up $200 million just over six months ago, Benchling isn’t sitting still. The cloud-based R&D platform developer collected another $100 million to help power its global expansion plans.
Xencor finally finds buyer for onetime lead drug, offloading autoimmune asset to Tesaro co-founder in backloaded deal
Xencor has finally found a buyer for its autoimmune disease bispecific antibody obexelimab. Almost three years after deciding to partner the drug in the wake of a failed phase 2, Xencor has offloaded the asset to Zenas BioPharma in a backloaded deal worth up to $480 million.
Manipulating the immune system’s T cells so they’re better able to recognize and kill cancer is the backbone of many immuno-oncology developments in recent years, but the treatments are far from perfect and they don’t work in every patient. In an effort to understand why, scientists at Brigham and Women’s Hospital and the Massachusetts Institute of Technology used high-power microscopy to watch breast cancer cells and T cells interact—and they made a discovery that could enhance immuno-oncology treatments.
Enanta Pharmaceuticals is shutting down work on its oral hepatitis B virus (HBV) program for EDP-721 after serious safety red flags were raised in a phase 1 study.
Medulloblastoma is a common brain tumor in children that becomes particularly tough to treat once it spreads. In an effort to find an immunotherapy that might offer hope to these young patients, scientists at Children’s National Hospital in Washington, D.C., used a specific type of DNA analysis to devise a novel therapy that’s showing promise in preclinical studies.
With more self-contained models potentially on their way to patients, the FDA is taking steps to remind healthcare providers of certain risks posed by leadless pacemakers, including the possibility of puncturing the heart wall during implantation.
Already a monolith in the clinical testing space, Labcorp is aiming to further swell its testing capabilities with the acquisition of contract research organization Toxikon.
Cassava Sciences is forging ahead with a second phase 3 trial of its troubled Alzheimer’s drug just three days after revealing a federal investigation into the company.